Skip to content
Monday 17 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
0.00%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Friday 25 February 2022 1:57 pm

J&J and three other drug distributors settle opioid crisis lawsuits for $26bn

By: Louis Goss

Add as a preferred source on Google

US pharma giant Johnson & Johnson, and three of America’s largest medical distributors, have agreed to pay $26bn (£19bn) to settle more than 3,000 lawsuits over the role they played in fuelling America’s opioid crisis.

New Jersey drugmaker J&J, and medicine distributors Cardinal Health, AmerisourceBergen, and Distributors McKesson, finalized a deal through which they will pay $26bn to settle thousands of lawsuits put forward by state and local governments who hold the companies responsible for the opioid crisis.

The firms had until today to decide whether to settle the cases out-of-court, after the deal was first announced in July 2021. The settlement will see J&J pay $5bn over the next nine years, while the distributors will pay $21bn over 18 years

The settlement comes after the Sackler family, which owns OxyContin drugmaker Purdue Pharma, offered to pay up to $6bn to settle claims out of court. Other major companies, including Israeli firm Teva, are also in discussions to settle opioid lawsuits out of court.

Read more

Nobel Peace Prize maker’s UK arm seeks administrator

Close-up of a golden Nobel Prize medal featuring Alfred Nobels profile on a dark, textured background.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Legal

Related Topics

  • Pharmaceuticals

Trending Articles

  • Jobs market ‘stops moving’ as employment costs weigh on hirers

  • House prices suffer biggest August slump in eight years 

  • Back bookshops in bid to rebuild high streets, Burnham urged

  • Aldi boss wades into supermarket ‘price-gouging’ row

  • Reform pledges £50bn savings in ‘generational’ benefits shake-up

More from Morning Wire

  • Nobel Peace Prize maker’s UK arm seeks administrator

    Business
    Close-up of a golden Nobel Prize medal featuring Alfred Nobels profile on a dark, textured background.
  • Rehlko Expands Power Plus™ Connected-Services Capabilities, Enhancing Value Across Installed Base

    Business Wire
  • Anthropic payout piles pressure on UK ministers in AI copyright row

    Tech
    Smartphone displaying the Claude by Anthropic AI assistant app, showing the app icon and interface.
  • Promega Achieves 100% Renewable Electricity Across Global Operations

    Business Wire
  • Starmer’s final act will expose firms to more bogus equality claims

    Opinion
    Business conference attendees networking at a corporate event with banners and presentation screens in the background
  • Burnham should go on a ‘cost of doing business’ tour

    Economics
    Andy Burnham, Mayor of Greater Manchester, in a dark suit and glasses, listening intently at a wooden table.
  • Alkermes to Report Second Quarter Financial Results on July 28, 2026

    Business Wire
  • Alkermes plc Reports Second Quarter 2026 Financial Results

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook